Fusion Pharmaceuticals Inc.’s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. Bristol Meyers Squibb Co. BMY, -1.61% announced plans Tuesday to acquire Rayze Bio Inc. RYZB, +100.85% for $4.1 billion. Meanwhile Eli Lilly & Co.’s LLY, ...

RayzeBio被Bristol Myers Squibb收购 - RayzeBio将被Bristol Myers Squibb以约41亿美元的全现金交易收购[2] Gracell被AstraZeneca收购 - Gracell将被AstraZeneca以每股2美元的现金收购[3] Daseke被TFI International收购 - Daseke将被TFI International以约11亿美元的全现金交易收购[5] Karuna Therapeutics被Bristol Myers Squibb收购 - Karuna Therapeutics将被Bristol Myers Squibb以约140亿美元的全现金交易收购[6]

收购交易 - 布里斯托尔-迈尔斯斯奎布公司宣布以41亿美元收购RayzeBio公司[1] - RayzeBio股东将获得104%的溢价[1] - RayzeBio股价在周五收盘后的消息后周二交易中翻倍[1] 公司产品线 - RayzeBio正在开发利用放射性粒子杀灭癌细胞的方法[4] - 其当前产品线包括治疗实体肿瘤的项目，包括胃肠胰神经内分泌肿瘤、小细胞肺癌和肝细胞癌[4]

公司收购 - RayzeBio被Bristol Myers Squibb以每股62.50美元的现金收购，总股权价值约为41亿美元[3] - Bristol Myers Squibb通过收购RayzeBio，将在固体肿瘤治疗领域建立存在，并将放射性荷载物定向传递给癌细胞，成为最有前途和增长最快的新治疗模式之一[5] 公司产品 - RayzeBio是一家临床阶段的放射性药物疗法公司，专注于锕系放射性药物疗法，目前的管线项目针对实体肿瘤，包括胃肠胰神经内分泌肿瘤（GEP-NETs）、小细胞肺癌、肝细胞癌等[3] - RayzeBio的主导项目RYZ101正在进行第3期临床试验，针对胃肠胰神经内分泌肿瘤和早期小细胞肺癌的治疗[2] 公司发展 - RayzeBio的平台具有潜在的重要IND引擎，通过利用全球药物开发能力和基础设施，未来将产生多个治疗候选药物[5] - RayzeBio正在印第安纳波利斯建设一家先进的内部制药工厂，预计2024年上半年开始GMP药物生产[9]

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors. RayzeBio is a clinical-stage radiopharmaceutical ther ...

Key TakeawaysU.S. equities continued their pre-Christmas rally in the last week of 2023, with the Dow, S&P 500, and Nasdaq all up.Intel received a $3.2 billion incentive deal from the Israeli government, and shares of the chipmaker rose.Bristol-Myers Squibb will pay $4.1 billion to buy RayzeBio as the drug maker moves to expand its cancer portfolio.Christmas may be over, but the so-called “Santa Claus rally” continued for U.S. equities at midday in the shortened final trading week of 2023. The Dow, S&P 500, ...

About this content About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.  Read more About the publisher Pr ...

收购交易 - 布里斯托尔迈尔斯斯奎布宣布将以约41亿美元收购RayzeBio，以加强其癌症药物业务[1] - 该交易将使布里斯托尔获得RayzeBio的晚期靶向癌症疗法RYZ101，该疗法通过将杀死细胞的放射性粒子与附着在肿瘤上的分子结合起来发挥作用[2] - 布里斯托尔表示将以每股62.50美元的现金收购RayzeBio，这相当于股票上次收盘价的104%溢价[6] 药物市场竞争 - 布里斯托尔正寻求交易，因为其两款畅销药物——血癌治疗药物Revlimid和抗凝血药Eliquis正面临仿制药竞争[3] - 其另一款畅销药物——癌症免疫疗法Opdivo，预计也将面临收入损失，因为该药物将在本十年后期失去专利保护[4] 财务影响 - RayzeBio的股价在盘前交易中几乎翻倍，达到60.9美元[7] - 布里斯托尔表示预计将主要通过新债务融资该交易。根据布里斯托尔的说法，该交易预计将使其2024年的调整每股利润减少约13美分[8]

Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion ...

Bristol Myers Squibb Co. BMY, +2.01% announced Tuesday an agreement to buy radiopharmaceutical therapeutics company RayzeBio Inc. RYZB, +9.37% in a deal valued at $4.1 billion. Under terms of the deal, Bristol Myers will pay $62.50 in cash for each RayzeBio share outstanding, which represents a premium of 104.4% over Friday’s closing price of $30.57. RayzeBio’s stock was halted for new until 7:30 a.m. Eastern and Bristol Myers’ stock tacked on 0.2% in premarket trading. “This transaction enhances our incre ...